Gosselies, Belgium – iTeos Therapeutics
SA, a biotechnology company developing novel cancer immunotherapies, today
announced the completion of an oversubscribed $75 million (€64 million) Series
B financing led by MPM Capital, with participation from additional new
investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All
existing investors also participated in this financing round including Fund +,
VIVES II and SRIW, as well as SFPI. Read the official press release here.
ChromaCure is a newly created spin-off company of ULB dedicated to develop first-in-class small molecule therapeutics for unmet needs in oncology, based on a very promising target. We are delighted to welcome them in our incubator. Discover the official press release here.Read more